To further determine the role of FAP+CAFs in gastric cancer resistance to anti-PD-1, we analyzed retrospective data from another 24 primary gastric cancer patients receiving combined anti-PD-1 immunotherapy who had not received antitumor therapy [Supplementary Table 3]. Here, FAP is linked to gastric cancer.